IMDX Earnings Date: Nov 9, 2026 (Estimated) — Insight Molecular Diagnostics Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is IMDX's next earnings date?
Insight Molecular Diagnostics Inc. (IMDX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $235,120.
How did IMDX do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Insight Molecular Diagnostics Inc. posted EPS of -$0.23 versus the -$0.25 estimate, a beat of 0.0%. Revenue was $239,000 against a $352,500 estimate. The stock's 1-day post-earnings move was -7.1%.
How much does IMDX stock move after earnings?
IMDX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 5 reports the stock moved an average of 12.2% (up or down) in the day after earnings.
About Insight Molecular Diagnostics Inc.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.25 | -0.23 | +0.00% | $239,000 | ✅ Beat | -7.13% | -10.48% | -14.05% |
| 2026-05-13 | Q1 2026 | -0.26 | -0.28 | -7.69% | $32,000 | ❌ Miss | +25.88% | +21.37% | +10.00% |
| 2026-03-26 | Q4 2025 | -0.24 | -0.27 | -12.50% | $1.1M | ❌ Miss | -13.38% | -8.52% | -6.57% |
| 2025-11-10 | Q3 2025 | -0.24 | -0.34 | -41.67% | $139,000 | ❌ Miss | +10.66% | -1.47% | -25.15% |
| 2025-08-11 | Q2 2025 | -0.24 | -0.30 | -25.00% | $518,000 | ❌ Miss | -3.83% | +2.30% | +14.94% |
| 2022-11-10 | -2.27 | -1.60 | — | $1.0M | ✅ Beat | — | — | — | |
| 2022-08-10 | -2.40 | -1.40 | — | $2.1M | ✅ Beat | — | — | — | |
| 2022-05-11 | -2.43 | -2.20 | — | $1.4M | ✅ Beat | — | — | — |
Showing last 8 quarters.